Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456865 · ClinicalTrials.gov registry record · NA
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
A NA study of Urge Urinary Incontinence, sponsored by MedtronicNeuro.
- Recruiting
- Registry status
- NA
- Development phase
- 256
- Enrollment target
- 1
- Study location
NCT07456865 is a NA study of Urge Urinary Incontinence that is actively recruiting participants, run by MedtronicNeuro. The registered enrollment target is 256 participants, above the 129-participant average among 4 other Urge Urinary Incontinence trials with a reported enrollment target (98% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07456865, a NA study of Urge Urinary Incontinence, is actively recruiting participants, sponsored by MedtronicNeuro.
- RECRUITING
- Registry status
- NA
- Development phase
- 256 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI
Conditions Studied
Interventions
- DEVICE Altaviva™ system
Study Locations (1)
Pennsylvania
- Institute for Female Pelvic Medicine and Reconstructive Surgery - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2032-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07456865
The ClinicalTrials.gov registry entry for NCT07456865 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 4 other Urge Urinary Incontinence trials with a reported enrollment target (98% higher). The listed sponsor is MedtronicNeuro, which has 51 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urge Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Altaviva™ system is the first listed.
NCT07456865 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07456865 about?
NCT07456865 is a clinical study titled "Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device". The purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI
What is the current status of trial NCT07456865?
This trial is currently recruiting. It is a NA study. The enrollment target is 256 participants. The study started on 2026-03-17. Estimated completion is 2032-11.
What conditions does trial NCT07456865 study?
This clinical trial studies the following conditions: Urge Urinary Incontinence.
What interventions are being tested in trial NCT07456865?
The interventions under investigation include: Altaviva™ system (DEVICE).
Who is sponsoring clinical trial NCT07456865?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07456865 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urge Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.